Prevalence and Impact of Polyvascular Disease in Patients With Acute Myocardial Infarction in the Contemporary Era of Percutaneous Coronary Intervention - Insights From the Japan Acute Myocardial Infarction Registry (JAMIR).

All-cause mortality Japan Acute Myocardial Infarction Registry (JAMIR) Major adverse cardiovascular events (MACE) Major bleeding Polyvascular disease

Journal

Circulation journal : official journal of the Japanese Circulation Society
ISSN: 1347-4820
Titre abrégé: Circ J
Pays: Japan
ID NLM: 101137683

Informations de publication

Date de publication:
23 Nov 2023
Historique:
medline: 27 11 2023
pubmed: 27 11 2023
entrez: 26 11 2023
Statut: aheadofprint

Résumé

This post hoc subanalysis aimed to investigate the impact of polyvascular disease (PolyVD) in patients with acute myocardial infarction (AMI) in the contemporary era of percutaneous coronary intervention (PCI).Methods and Results: The Japan Acute Myocardial Infarction Registry (JAMIR), a multicenter prospective registry, enrolled 3,411 patients with AMI between December 2015 and May 2017. Patients were classified according to complications of a prior stroke and/or peripheral artery disease into an AMI-only group (involvement of 1 vascular bed [1-bed group]; n=2,980), PolyVD with one of the complications (2-bed group; n=383), and PolyVD with both complications (3-bed group; n=48). The primary endpoint was all-cause death. Secondary endpoints were major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and major bleeding. In the 1-, 2-, and 3-bed groups, the cumulative incidence of all-cause death was 6.8%, 17.5%, and 23.7%, respectively (P<0.001); that of MACE was 7.4%, 16.4%, and 33.8% (P<0.001), respectively; and that of major bleeding was 4.8%, 10.0%, and 13.9% (P<0.001), respectively. PolyVD was independently associated with all-cause death (hazard ratio [HR] 2.21; 95% confidence interval [CI], 1.48-3.29), MACE (HR 2.07; 95% CI 1.40-3.07), and major bleeding (HR 1.68; 95% CI 1.04-2.71). PolyVD was significantly associated with worse outcomes, including thrombotic and bleeding events, in the contemporary era of PCI in AMI patients.

Sections du résumé

BACKGROUND BACKGROUND
This post hoc subanalysis aimed to investigate the impact of polyvascular disease (PolyVD) in patients with acute myocardial infarction (AMI) in the contemporary era of percutaneous coronary intervention (PCI).Methods and Results: The Japan Acute Myocardial Infarction Registry (JAMIR), a multicenter prospective registry, enrolled 3,411 patients with AMI between December 2015 and May 2017. Patients were classified according to complications of a prior stroke and/or peripheral artery disease into an AMI-only group (involvement of 1 vascular bed [1-bed group]; n=2,980), PolyVD with one of the complications (2-bed group; n=383), and PolyVD with both complications (3-bed group; n=48). The primary endpoint was all-cause death. Secondary endpoints were major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and major bleeding. In the 1-, 2-, and 3-bed groups, the cumulative incidence of all-cause death was 6.8%, 17.5%, and 23.7%, respectively (P<0.001); that of MACE was 7.4%, 16.4%, and 33.8% (P<0.001), respectively; and that of major bleeding was 4.8%, 10.0%, and 13.9% (P<0.001), respectively. PolyVD was independently associated with all-cause death (hazard ratio [HR] 2.21; 95% confidence interval [CI], 1.48-3.29), MACE (HR 2.07; 95% CI 1.40-3.07), and major bleeding (HR 1.68; 95% CI 1.04-2.71).
CONCLUSIONS CONCLUSIONS
PolyVD was significantly associated with worse outcomes, including thrombotic and bleeding events, in the contemporary era of PCI in AMI patients.

Identifiants

pubmed: 38008436
doi: 10.1253/circj.CJ-23-0477
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Riku Arai (R)

Division of Cardiology, Department of Medicine, Nihon University School of Medicine.

Yasuo Okumura (Y)

Division of Cardiology, Department of Medicine, Nihon University School of Medicine.

Nobuhiro Murata (N)

Division of Cardiology, Department of Medicine, Nihon University School of Medicine.

Daisuke Fukamachi (D)

Division of Cardiology, Department of Medicine, Nihon University School of Medicine.

Satoshi Honda (S)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center.

Kensaku Nishihira (K)

Department of Cardiology, Miyazaki Medical Association Hospital.

Sunao Kojima (S)

Department of Internal Medicine, Sakurajyuji Yatsushiro Rehabilitation Hospital.

Misa Takegami (M)

Department of Preventive Medicine and Epidemiology, National Cerebral and Cardiovascular Center.
Department of Public Health and Health Policy, Graduate School of Medicine, The University of Tokyo.

Yasuhide Asaumi (Y)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center.

Jun Yamashita (J)

Department of Cardiology, Tokyo Medical University Hospital.

Mike Saji (M)

Department of Cardiovascular Medicine, Toho University Faculty of Medicine.

Kiyoshi Hibi (K)

Division of Cardiology, Yokohama City University Medical Center.

Jun Takahashi (J)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine.

Yasuhiko Sakata (Y)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center.

Morimasa Takayama (M)

Department of Cardiology, Sakakibara Heart Institute.

Tetsuya Sumiyoshi (T)

Department of Cardiology, Sakakibara Heart Institute.

Hisao Ogawa (H)

Kumamoto University.

Kazuo Kimura (K)

Division of Cardiology, Yokohama City University Medical Center.

Satoshi Yasuda (S)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine.

Classifications MeSH